Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 18;331(23):2041-2043.
doi: 10.1001/jama.2024.7112.

Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023

Joyce M Lee  1 , Mona Sharifi  2 , Lauren Oshman  3 , Dina H Griauzde  4 , Kao-Ping Chua  1
Affiliations

Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023

Joyce M Lee et al. JAMA. .
No abstract available

Plain language summary

This study uses data from US retail pharmacies to assess national GLP-1RA dispensing to adolescents and young adults from 2020-2023.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Lee reported receiving personal fees from GoodRx, Tandem Diabetes Care, and Sanofi outside the submitted work. Dr Sharifi reported receiving grants from NIH during the conduct of the study; and subcontract, personal fees, and nonfinancial support from American Academy of Pediatrics outside the submitted work. Dr Oshman reported stock investment from Eli Lilly (divested 2022) and Abbott (divested 2022) outside the submitted work. Dr Griauzde reported receiving grants from NIH/NIDDK outside the submitted work. Dr Chua reported receiving personal fees from the Benter Foundation and US Department of Justice outside the submitted work.

Figures

Figure.
Figure.. Monthly Number of US Adolescents and Young Adults With ≥1 Dispensed Prescription for Any Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Specific Medications, January 2020-December 2023
Tirzepatide is only approved in adults, but off-label use in adolescents is possible. Due to low numbers, dispensing of the oral formulation of semaglutide approved for type 2 diabetes is not shown.
See this image and copyright information in PMC

References

    1. Alhiary R, Kesselheim AS, Gabriele S, Beall RF, Tu SS, Feldman WB. Patents and regulatory exclusivities on GLP-1 receptor agonists. JAMA. 2023;330(7):650-657. doi:10.1001/jama.2023.13872 - DOI - PMC - PubMed
    1. Cooper DM, Rothstein MA, Amin A, Hirsch JD, Cooper E. Unintended consequences of glucagon-like peptide-1 receptor agonists medications in children and adolescents: a call to action. J Clin Transl Sci. 2023;7(1):e184. doi:10.1017/cts.2023.612 - DOI - PMC - PubMed
    1. Eli Lilly . FDA approves Lilly’s Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Published May 13, 2022. Accessed November 15, 2023. https://investor.lilly.com/news-releases/news-release-details/fda-approv...
    1. Novo Nordisk . FDA approves once-weekly Wegovy injection for the treatment of obesity in teens aged 12 years and older. Published December 23, 2022. Accessed November 29, 2023. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=1...
    1. Food and Drug Administration . FDA approves new medication for chronic weight management. Published November 8, 2023. Accessed March 9, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-new-med...

Publication types

MeSH terms

Substances